Embolization Particle Market Size, Share, Growth, and Industry Analysis, By Type (Microspheres, Particles (e.g. PVA Particles, Gelfoam Particles), Drug-eluting Beads (DEBs) and Radio-Embolic Microspheres (e.g. Therasphere and SIRSphere)), By Application (Uterine Fibroid Embolization, Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH), Liver Tumor Embolization, Trauma Embolization and Others) and Regional Forecast to 2035

EMBOLIZATION PARTICLE MARKET REPORT OVERVIEW

The global Embolization Particle Market size estimated at USD 3496.73 million in 2026 and is projected to reach USD 11827.74 million by 2035, growing at a CAGR of 14.5% from 2026 to 2035.

Embolization particles serve as medical devices intended for blocking blood flow to designated areas of the human body for treating tumors and arteriovenous malformations and fibroids.

• • 

    Download Free sample to learn more about this report.

KEY FINDINGS

• Market Size and Growth: The Embolization Particle Market size was USD 2667.17 Million in 2024, is projected to grow to USD 3120 Million by 2025 and exceed USD 9021.75 Million by 2033, with a CAGR of 14.5%.

• Key Market Driver: Rising prevalence of cancer cases is fueling demand, with nearly 20 million new cases diagnosed worldwide in 2023 according to WHO, many requiring minimally invasive embolization procedures.

• Major Market Restraint: Limited access to advanced interventional radiology in developing nations is slowing adoption, as more than 45% of low-income countries report shortages of trained specialists and modern catheterization labs.

• Emerging Trends: Demand for drug-eluting beads is accelerating, with adoption rates crossing 30% of interventional oncology cases in North America by 2024, reflecting a push toward targeted therapies.

• Regional Leadership: North America dominates the space, accounting for over 40% of global procedures in 2024, driven by higher healthcare expenditure and robust reimbursement policies in the U.S.

• Competitive Landscape: The field is moderately consolidated, with around 12 leading global players such as Boston Scientific and Merit Medical holding more than 55% of the total market share.

• Market Segmentation: Microspheres represent the largest product category, accounting for nearly 50% of total usage in 2024, widely applied in uterine fibroid and liver cancer embolization procedures.

• Recent Development: In 2024, Boston Scientific expanded its interventional oncology portfolio by launching new calibrated microspheres across Europe, reaching 10 additional countries within the first six months of release.

COVID-19 IMPACT

Embolization Particle Industry Had a Negative Effect Due to Delayed Elective Procedures and Reduced Patient Volume during COVID-19 Pandemic

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The vast pressure on healthcare providers during the pandemic caused numerous elective medical operations with embolization therapy among them to be either suspended or canceled while COVID-19 cases gained priority status. Healthcare facilities directed their attention to COVID-19 patient care resulting in fewer individuals who underwent embolization procedures.

LATEST TRENDS

"Development of Targeted and Customized Embolization Particles to Propel Market Growth"

The medical field develops embolization particles which become customized to treat patients through the use of their unique tumor or vascular characteristics. Customized embolic procedures serve to improve treatment outcomes by decreasing side effects and raising overall performance. The growing demand for the embolization market relies on microspheres because they provide localized therapeutic methods. Patients can simultaneously benefit from tumor treatment through direct drug application in addition to embolization through the use of microspheres containing chemotherapeutic drugs or radioactive isotopes for transarterial chemoembolization (TACE) liver cancer therapy.

• • 

    Download Free sample to learn more about this report.

EMBOLIZATION PARTICLE MARKET SEGMENTATION

By Type

Microspheres: Microspheres are advanced embolization particles used in minimally invasive procedures to block blood flow in targeted areas. They are widely applied in treating tumors, vascular malformations, and other clinical conditions, offering precision, biocompatibility, and controlled therapeutic effects.

Microspheres Market Size, Share and CAGR are valued at USD 1600 million in 2024, holding a market share of 60% with a CAGR of 14.8% from 2025-2033.

Top 5 Major Dominant Countries in the Microspheres Segment

• United States dominates with USD 600 million market size, 37% share and CAGR of 14.5%, driven by high adoption of minimally invasive procedures and advanced healthcare infrastructure.
• Germany holds USD 250 million, 16% share with CAGR of 14.7%, supported by technological advancements and strong clinical adoption.
• Japan reports USD 200 million, 12% share and CAGR of 14.2%, reflecting rising demand for precise embolization therapies and aging population.
• China exhibits USD 300 million market size, 18% share with CAGR of 15.0%, fueled by growing healthcare spending and awareness of minimally invasive treatments.
• France maintains USD 150 million, 9% share with CAGR of 14.6%, supported by advanced healthcare facilities and skilled medical practitioners.

Particles (e.g. PVA Particles, Gelfoam Particles): PVA and Gelfoam particles are commonly used embolization materials that block blood vessels effectively. They are highly versatile, cost-effective, and widely adopted in interventional radiology for various clinical treatments, including tumor devascularization and vascular malformations.

Particles Market Size, Share and CAGR are projected at USD 1067.17 million in 2024, representing 40% market share with a CAGR of 14.1% from 2025-2033.

Top 5 Major Dominant Countries in the Particles Segment

• United States holds USD 400 million, 38% share with CAGR of 14.3%, driven by extensive use in clinical procedures and established healthcare systems.
• Germany reports USD 150 million, 14% share with CAGR of 14.0%, supported by strong adoption in interventional radiology centers.
• Japan exhibits USD 120 million, 11% share with CAGR of 13.8%, reflecting consistent usage in minimally invasive embolization therapies.
• China maintains USD 250 million, 23% share with CAGR of 14.5%, fueled by rising healthcare access and awareness of embolization treatments.
• France shows USD 80 million, 8% share with CAGR of 14.2%, influenced by growing expertise in interventional radiology and clinical applications.

By Application

Uterine Fibroid Embolization: Uterine Fibroid Embolization (UFE) is a minimally invasive procedure used to treat symptomatic uterine fibroids. It blocks blood supply to fibroids, causing them to shrink, reducing pain and bleeding while preserving fertility and uterus function, and providing faster recovery.

Uterine Fibroid Embolization Market Size, Share and CAGR are projected at USD 1700 million in 2024 with a 64% share and CAGR of 14.7% from 2025-2033.

Top 5 Major Dominant Countries in the Uterine Fibroid Embolization Segment

• United States leads with USD 700 million market size, 41% share and CAGR of 14.6%, driven by high awareness, advanced technology adoption, and strong healthcare infrastructure.
• Germany holds USD 250 million, 15% share with CAGR of 14.8%, supported by widespread interventional radiology expertise.
• Japan reports USD 200 million, 12% share with CAGR of 14.5%, reflecting aging population and preference for non-surgical treatments.
• China exhibits USD 350 million, 21% share with CAGR of 15.0%, fueled by increasing access to minimally invasive procedures.
• France maintains USD 100 million, 6% share with CAGR of 14.4%, supported by skilled medical professionals and hospital adoption.

Prostatic Artery Embolization (treatment for Benign Prostatic Hyperplasia or BPH): Prostatic Artery Embolization (PAE) is a non-surgical intervention to treat BPH. It reduces prostate size by obstructing blood flow, alleviating urinary symptoms, minimizing recovery time, and offering an alternative to traditional surgery.

PAE Market Size, Share and CAGR are valued at USD 967.17 million in 2024, representing 36% share with a CAGR of 14.3% from 2025-2033.

Top 5 Major Dominant Countries in the Prostatic Artery Embolization Segment

• United States dominates with USD 500 million market size, 52% share and CAGR of 14.5%, driven by increasing prevalence of BPH and advanced healthcare facilities.
• Germany reports USD 150 million, 16% share with CAGR of 14.2%, supported by skilled interventional radiologists and technology adoption.
• Japan holds USD 100 million, 10% share with CAGR of 14.0%, reflecting growing awareness of minimally invasive therapies.
• China exhibits USD 180 million, 19% share with CAGR of 15.0%, fueled by expanding healthcare access and aging male population.
• France maintains USD 37.17 million, 4% share with CAGR of 14.1%, driven by adoption in clinical centers and research support.

Driving Factors

"Rising Prevalence of Cancer and Tumors to Drive Market Advancement"

One of the key driving factors in the Embolization Particle market growth is Rising Prevalence of Cancer and Tumors. The embolization particle market experiences growth due to the rising numbers of liver cancer alongside renal cancer and uterine fibroids cases. Both TACE and radioembolization treatment procedures encompass the utilization of embolization particles in their delivery of cancer therapies to various cancer types. Non-invasive treatments with abbreviated recovery intervals are gaining more public acceptance hence embolization emerges as a preferred medical choice resulting in rising use of embolization particles in cancer care.

"Increasing Preference for Minimally Invasive Procedures to Expand the Market"

Medical practices moving toward noninvasive procedures constitutes the primary driver of market growth for embolization particles. The approach features smaller incisions and causes reduced pain and delivers quicker healing as well as diminished medical complications than conventional surgical methods. Embolization continues to gain popularity because it delivers targeted treatment while shortening recovery periods so healthcare providers and patients choose it often. The market experiences growth because of mounting patient and healthcare provider preference for embolization.

Restraining Factors

"High Cost of Treatment Potential Impediments to Market Growth"

The cost of embolization procedures becomes high when healthcare providers use complicated embolization particles like drug-eluting or microspheres. The overall expense includes both the particle price alongside the medical procedures with imaging tests and expert healthcare services costs. Embolization treatments face availability challenges because of their high expense which restricts patients' healthcare access primarily in regions with limited healthcare funding such as low- and middle-income settings. The limited use of embolization procedures occurs because such treatments remain out of reach in these regions.

 Opportunity

"Rising Prevalence of Chronic Diseases To Create Opportunity for the Product in the Market"

The increasing number of cancer diagnoses in the population mostly affects liver cancer and lung cancer and solid tumors thus driving high demand for transarterial chemoembolization (TACE) treatments. The medical field is starting to adopt embolization particles as an alternative and less complex approach for treating untreatable tumors.

Challenge

"Lack of Skilled Professionals Could Be a Potential Challenge for Consumers"

The medical procedures of embolization require physician specialists who both posses extensive training in interventional radiology and catheter-based therapeutic techniques. The implementation of embolization procedures suffers due to insufficient professionals who have the required experience in certain areas. The procedure depends on state-of-the-art imaging methods (CT scans, MRI and fluoroscopy) to position the catheter along with embolization particles properly.

• • 

    Download Free sampleto learn more about this report.

•  

EMBOLIZATION PARTICLE MARKET REGIONAL INSIGHTS

North America

North America leads the Embolization Particle Market due to advanced healthcare infrastructure, increasing prevalence of fibroids and BPH, and strong adoption of minimally invasive procedures. Rising investments in interventional radiology technology further drive market growth in this region.

North America Market Size is projected at USD 1200 million in 2024 with a 45% share and CAGR of 14.2% from 2025-2033.

North America - Major Dominant Countries in the Embolization Particle Market

• United States dominates with USD 1000 million market size, 50% share and CAGR of 14.5%, driven by high adoption of embolization procedures and advanced medical facilities.
• Canada has USD 150 million, 12% share with CAGR of 14.0%, supported by rising interventional radiology adoption and clinical expertise.
• Mexico holds USD 30 million, 3% share with CAGR of 13.8%, reflecting growing awareness and healthcare access.
• Puerto Rico exhibits USD 15 million, 1.5% share with CAGR of 14.1%, influenced by modern medical infrastructure.
• Dominican Republic shows USD 5 million, 0.5% share with CAGR of 13.9%, supported by clinical adoption of embolization therapies.

Europe

Europe's Embolization Particle Market is driven by high adoption of minimally invasive procedures, availability of skilled interventional radiologists, and increasing prevalence of uterine fibroids and BPH. Healthcare investment and technological advancements further boost regional growth.

Europe Market Size is projected at USD 800 million in 2024 with a 30% share and CAGR of 14.4% from 2025-2033.

Europe - Major Dominant Countries in the Embolization Particle Market

• Germany leads with USD 250 million, 31% share and CAGR of 14.6%, supported by advanced medical facilities and interventional radiology expertise.
• France has USD 200 million, 25% share with CAGR of 14.3%, reflecting widespread adoption in clinical centers and research support.
• United Kingdom exhibits USD 150 million, 19% share with CAGR of 14.2%, driven by growing awareness of embolization therapies.
• Italy maintains USD 100 million, 12% share with CAGR of 14.1%, supported by urban hospitals and modern medical procedures.
• Spain shows USD 100 million, 13% share with CAGR of 14.0%, fueled by minimally invasive procedure adoption and healthcare access.

Asia

Asia’s Embolization Particle Market is witnessing growth due to rising healthcare infrastructure, increasing awareness of minimally invasive procedures, growing prevalence of fibroids and BPH, and expanding reimbursement policies supporting interventional radiology adoption.

Asia Market Size is projected at USD 500 million in 2024 with 19% share and CAGR of 14.6% from 2025-2033.

Asia - Major Dominant Countries in the Embolization Particle Market

• China dominates with USD 250 million, 50% share and CAGR of 15.0%, fueled by increasing healthcare access and technology adoption in urban hospitals.
• Japan holds USD 120 million, 24% share with CAGR of 14.4%, reflecting growing geriatric population and preference for minimally invasive therapies.
• India exhibits USD 80 million, 16% share with CAGR of 14.5%, driven by awareness and rising interventional radiology centers.
• South Korea maintains USD 30 million, 6% share with CAGR of 14.3%, supported by advanced clinical expertise.
• Singapore shows USD 20 million, 4% share with CAGR of 14.2%, influenced by high adoption of modern medical procedures.

Middle East and Africa

Middle East and Africa Embolization Particle Market is growing due to increasing healthcare investments, rising awareness of minimally invasive procedures, expansion of clinical centers, and adoption of interventional radiology to treat fibroids and BPH effectively.

Middle East and Africa Market Size is projected at USD 167.17 million in 2024 with 6% share and CAGR of 14.0% from 2025-2033.

Middle East and Africa - Major Dominant Countries in the Embolization Particle Market

• United Arab Emirates leads with USD 50 million, 30% share and CAGR of 14.2%, driven by advanced medical infrastructure and adoption of minimally invasive procedures.
• Saudi Arabia holds USD 40 million, 24% share with CAGR of 14.0%, supported by growing interventional radiology awareness.
• South Africa exhibits USD 35 million, 21% share with CAGR of 14.1%, fueled by expanding healthcare facilities and modern treatments.
• Egypt maintains USD 25 million, 15% share with CAGR of 13.9%, reflecting increasing healthcare access and clinical adoption.
• Nigeria shows USD 17.17 million, 10% share with CAGR of 14.0%, driven by rising healthcare awareness and hospital adoption.

KEY INDUSTRY PLAYERS

"Key Players Transforming the Embolization Particle Landscape through Innovation and Global Strategy"

Key enterprise players are shaping the Embolization Particle marketplace through strategic innovation and marketplace growth. The medical field sees substantial financial investment behind the research of improved embolic agents including drug-eluting microspheres alongside biodegradable embolic materials that provide enhanced therapeutic outcomes with lower adverse effects. The new sophisticated embolic agents outperform conventional medical embolization matter while delivering better clinical results to healthcare patients.

List Of Market Players Profiled

• BTG Medical (U.K.)
• Cook Medical (U.S.)
• Merit Medical (U.S.)
• Boston Scientific Corporation (U.S.)
• Sirtex Medical (U.S.)

INDUSTRIAL DEVELOPMENT

May 2023: The acquisition involved Merit Medical Systems, Inc. paying $100 million through cash to acquire both the BioSentry® Biopsy Tract Sealant System and dialysis catheter devices from AngioDynamics, Inc. 

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated time frame. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.